Axillary Hyperhidrosis Treatment Market

Axillary Hyperhidrosis Treatment Market Snapshot

According to Future Market Insights (FMI) analysis in a recent market survey, the global axillary hyperhidrosis treatment market was valued at USD 1.6 Billion in 2022 and is expected to reach USD 3.3 Billion by 2033.

Market Outlook:

Data Points	Market Insights
Market Value 2022	USD 1.6 Billion
Market Value 2023	USD 1.8 Billion
Market Value 2033	USD 3.3 Billion
CAGR 2023 to 2033	6.7%
Share of Top 5 Countries	53.6%
Key Players	The key players in the axillary hyperhidrosis treatment market are Allergan plc. (AbbVie); Journey Medical Corporation (Dermira, Inc.); Riemann A/S (Orkla); SweatBlock; Certain Dri; miraDry; Inc. (Sientra); STRATUS PHARMACEUTICALS INC; Duradry; Pers?n & Covey; GlaxoSmithKline Plc.; Carpe; SweatStop® International; CORAD Healthcare; ZeroSweat

Anti-sweat injections are nowadays considered to be the best option for treating axillary hyperhidrosis as these don't require any incisions.

Doctors are now employing Botox as a successful alternative to treat hyperhidrosis for individuals who want long-lasting results or for whom conventional antiperspirants are ineffective. The FDA has licensed Botox for the treatment of axillary hyperhidrosis in individuals who frequently perspire.

• The less invasive aspect of Botox injections, the less pain when administered into the armpits, and the generally safe technique are factors that have driven people to select Botox treatment for long-term results. Further growth is anticipated for this trend, which will help the market flourish.

Medicated wipes and gels are also effective substitutes. These products contain active ingredients such as aluminum chloride or aluminum zirconium tetrachlorohydrex glycine, which work by blocking sweat ducts and reducing the amount of sweat produced.

One advantage of medicated wipes and gels is that they are non-invasive and do not require any medical procedures. However, another advantage is that they can be more effective than other traditional treatment options. Medicated wipes and gels contain higher concentrations of active ingredients, which can provide longer-lasting and more reliable results.

Overall, the increasing use of medicated wipes and gels in the treatment of hyperhidrosis is likely due to their convenience, efficacy, and safety, which will boost the market in the coming years.

Sales Analysis of Axillary Hyperhidrosis Treatment Market from 2017 to 2022 Vs Market Outlook for 2023 to 2033

Sales of the axillary hyperhidrosis treatment market grew at a CAGR of 7.2% between 2017 to 2022. Axillary hyperhidrosis treatment market contributes 5.1% revenue share to the global dermatology therapeutics market in 2022.

The increasing availability of over-the-counter and labelled medications for the treatment of axillary hyperhidrosis will further result in higher uptake of various treatment options such as antiperspirants, thus leading to market expansion. Because of their easy availability and affordability, antiperspirants are typically the first form of treatment recommended by a dermatologist worldwide for axillary hyperhidrosis.

• Dermatologists recommend clinical-strength antiperspirants or regular antiperspirants to their axillary hyperhidrosis patients as they are simple to use, well tolerated by patients, and have minimalistic side effects. The market will continue to grow as a result of the strong recommendation for antiperspirants as the first-line treatment for hyperhidrosis.
• As per the statistics provided by Sweathelp Organization, 2022, a significant percentage of the overall global population has hyperhidrosis. Of these, more than 60% of people suffer from sweating localized to the armpits (axillary diseases).

With the advancement of therapies such as iontophoresis and antiperspirants, axillary hyperhidrosis can now be treated more successfully than in the past. For the treatment of hyperhidrosis, more recent treatment options like miraDry, Botox injections, and lasers have significantly increased patient satisfaction and emerged as effective treatment options for axillary hyperhidrosis, which has led to the higher adoption of such products and therapies in the global market.

Prevalence of diabetes and obesity increases the chances of secondary hyperhidrosis in patients. Diabetes can lead to nerve damage that can affect the body's ability to regulate sweating. Menopause can also lead to hormonal changes that affect sweating. Obesity can lead to excessive sweating due to increased body mass and associated heat production.

• According to a study in the 9th edition of the International Diabetes Federation Diabetes Atlas, 463 million people worldwide were living with diabetes in 2019. Prevalence is expected to increase to 578 million in 2030 and 700 million in 2045. Consequently, the increasing prevalence of diabetes will lead to an increase in hyperhidrosis disorders such as axillary hyperhidrosis in patients, which will result in more patients seeking hyperhidrosis treatment.

Considering this, FMI expects the global axillary hyperhidrosis treatment market to grow at a CAGR of 6.7% through the forecasted years.

What are the Key Opportunities in the Axillary Hyperhidrosis Treatment Market?

There is a lack of awareness regarding axillary hyperhidrosis, which is excessive sweating in the armpits Many people who suffer from this condition may not realize that it is a medical condition that can be treated. They may be embarrassed to talk about it, or believe it is just a normal reaction of their body to heat or stress.

As a result, many people with axillary hyperhidrosis do not seek treatment, which can lead to social isolation, anxiety, and low self-esteem. Secondly, healthcare providers may not recognize the condition or may not know how to effectively treat it.

Healthcare professionals are also experimenting with various combination therapies/treatments and seeing positive results in their patients, especially with oral medications. Oral medications are generally not a viable, long-term, sole option due to their side effects. Instead, other treatments can be combined with them to achieve the best results, and new formulations can make them easier for more patients.

• Botulinum toxin injections and oral medications are an example of combined treatment for hyperhidrosis. Botulinum toxin injections are a common treatment for hyperhidrosis, but they may not be effective for axillary hyperhidrosis or in all patients. Oral medications such as anticholinergics or beta blockers may be used in combination with botulinum toxin injections to reduce sweating.

Increased testing of combination therapies in patients will pave the way for new drug discoveries and treatment options, ultimately leading to the introduction of new products into the market.

Which Factors Could Possibly Restrain the Growth of Axillary Hyperhidrosis Treatment Market?

Many people suffering from axillary hyperhidrosis are not aware that there are treatments available for their condition. This lack of awareness could result in fewer patients seeking treatment, thereby limiting the growth of the market.

Some of the treatments for axillary hyperhidrosis, such as antiperspirants and botox injections, may have side effects that could discourage patients to seek treatment and pursue alternative therapies, such as herbal remedies or acupuncture, instead of conventional medical treatments, which could limit the growth of the market for conventional treatments.

• While antiperspirants are generally considered safe and effective, some people may experience skin irritation, redness, or itching, particularly if they have sensitive skin. In rare cases, antiperspirants may cause an allergic reaction, which could lead to more severe symptoms such as hives, difficulty breathing, or swelling of the face, lips, tongue, or throat.
• Botox injections work by blocking the nerve signals that cause sweating in the underarms. While generally safe, they can cause side effects such as pain or bruising at the injection site, headache, flu-like symptoms, or dry mouth. In rare cases, Botox injections may cause more serious side effects such as muscle weakness, difficulty breathing, or difficulty swallowing.

The potential side effects of antiperspirants and Botox injections may deter some patients from using these treatments, and could limit their uptake.

These factors are expected to hamper revenue growth of the axillary hyperhidrosis treatment market over the forecast period.

Country-wise Insights

What Makes the USA the Dominating Country in the Axillary Hyperhidrosis Treatment Market?

The USA axillary hyperhidrosis treatment market is expected to register a CAGR of 5.0% during the forecast period.

The high prevalence of primary and secondary hyperhidrosis in the United States will accelerate the acceptance of various treatment alternatives.

• According to the American Journal of Clinical Dermatology, hyperhidrosis affects over 4.8% of the USA population, or more than 15 million people. Of those 15 million people, more than 10 million suffer from axillary hyperhidrosis, and the majority of those affected report that it negatively impacts their social life, well-being, and mental health. Hyperhidrosis is most common in people between the ages of 20 and 60.

Due to the high prevalence, more treatments, including over-the-counter products such as antiperspirants and wipes, will experience a high adoption rate among patients. The demand for axillary hyperhidrosis treatment will increase due to high prevalence, which will drive the expansion of the market.

Why is Germany considered to be a Lucrative Segment for Axillary Hyperhidrosis Treatment Market in Europe?

Germany dominated the European market for axillary hyperhidrosis treatment and accounted for around 22.2% of the market share in 2022.

Over the years, miraDry has completely overshadowed these invasive procedures owing to its non-invasive nature while providing the treatment.

Since 2014, Munich’s German Hyperhidrosis Center (DHHZ) has been offering this treatment and is the first miraDry treatment facility certified in Germany and Europe. Since 2015, miraDry has also been further developed and improved for the treatment of excessive sweating in the groin, buttocks, and trunk.

The safe and successful use of miraDry treatments in Germany will influence other European countries to also opt for this treatment method, ultimately expanding the overall market.

What Makes China an Emerging Market for Axillary Hyperhidrosis Treatment?

China is projected to be the most attractive market in the axillary hyperhidrosis treatment, and is expected to grow over a significant CAGR of 8.3%.

The axillary hyperhidrosis treatment market in China is expected to grow significantly in the coming years due to several factors.

One of the main factors driving the growth of the axillary hyperhidrosis treatment market in China is the increasing awareness of the condition among the general public and healthcare professionals. As more people become aware of the condition, they are more likely to seek treatment, which is leading to increased demand for treatments for axillary hyperhidrosis.

Another factor contributing to the growth of the axillary hyperhidrosis treatment market in China is the increasing availability of advanced medical technologies and treatments.

China has made significant investments in its healthcare infrastructure, and many new hospitals and clinics have been built in recent years. This has allowed for the introduction of advanced treatments such as botox injections and surgery, which were not widely available in the past.

Category-wise Insights

Why Drug Therapy Is Largely Adopted Treatment Option for Axillary Hyperhidrosis?

The drug therapy segment held the major chunk of about 62.7% in global market by the end of 2022.

Drug therapy is a non-invasive treatment option that does not require any surgical procedures or injections. This makes it a less risky and more comfortable option for patients who may be apprehensive about more invasive treatments.

Certain medications, such as antiperspirants and oral anticholinergic drugs, have been shown to be effective in reducing excessive sweating in patients with axillary hyperhidrosis. These medications can be effective in reducing sweat production with minimal side effects. This makes it a safer and more tolerable option for patients who may be concerned about potential side effects.

Overall, drug therapy is a widely adopted treatment option for axillary hyperhidrosis due to its non-invasive nature, efficacy, accessibility, cost-effectiveness, and minimal side effects.

Which Distribution Channel Dominates the Global Market in 2022?

The retail pharmacy segment accounted for revenue share of 34.2% in the global market at the end of 2022.

Retail pharmacies offer convenient access to treatment options, with many providing over-the-counter and prescription medications for a range of conditions, including axillary hyperhidrosis. Patients can typically purchase these treatments without an appointment, making it more convenient for them to manage their condition.

Overall, retail pharmacy offers a convenient and accessible distribution channel for axillary hyperhidrosis treating products, making it the largest channel for these treatments.

Competitive Landscape

Key players in the market are focused on increase their product portfolio to strengthen their position in the axillary hyperhidrosis treatment market, and also to expand their footprint in emerging markets. The key strategy adopted by manufacturers to gain competitive edge in the market are the pricing strategies, market strategies, technological advancements, regulatory compliance and acquisition & distribution agreement of other companies to expand their business.

For instance

• In April 2021, Journey Medical Corporation and Dermira, Inc subsidiary of Eli Lilly and Company, entered into an agreement to acquire QBREXZA®.
• In May 2020, AbbVie announced that it had completed the acquisition of Allergan Plc after obtaining all regulatory approvals required under the transaction agreement and obtaining the approval of the Irish High Court.

Similarly, recent developments have been tracked by the team at Future Market Insights related to companies in the axillary hyperhidrosis treatment market space, which are available in the full report

Scope of the Axillary Hyperhidrosis Treatment Report

Attribute	Details
Forecast Period	2023 to 2033
Historical Data Available for	2017 to 2022
Market Analysis	USD Million for Value
Key Regions Covered	North America; Latin America; Europe; South Asia; East Asia; Oceania; Middle East and Africa (MEA)
Key Countries Covered	USA, Canada, Brazil, Mexico, Argentina, Germany, United kingdom, France, Italy, Spain, Russia, BENELUX, Nordics, China, Japan, South Korea, India, Thailand, Indonesia, Malaysia, Australia, New Zealand, Türkiye, South Africa, North Africa and GCC Countries
Key Segments Covered	Treatment, Distribution Channel, and Region
Key Companies Profiled	Allergan plc. (AbbVie); Journey Medical Corporation (Dermira, Inc.); Riemann A/S (Orkla); SweatBlock; Certain Dri; miraDry, Inc. (Sientra); STRATUS PHARMACEUTICALS INC; Duradry; Persn & Covey; GlaxoSmithKline Plc.; Carpe; SweatStop® International; CORAD Healthcare; ZeroSweat
Report Coverage	Market Forecast, Competition Intelligence, DROT Analysis, Market Dynamics and Challenges, Strategic Growth Initiatives
Customization & Pricing	Available upon Request

Key Segments Covered in Axillary Hyperhidrosis Treatment Industry Research

By Treatment:

• Drug Therapy
  • Antiperspirants (Both OTC & Rx)
    • Antiperspirants Spray
    • Antiperspirants Roll-On
    • Antiperspirants Wipes
    • Antiperspirants Lotion & Gel
  • Antihypertensive Drugs
  • Anticholinergic Agents
  • Alpha-Adrenergic Agonists
• Botulinum Toxins
• Medicated Wipes
• Microwave Therapy

By Distribution Channel:

• Hospitals
• General Physician’s Clinics
• Retail Pharmacy Chains
• Drug Stores
  • Online Sales
  • Manufacturer websites

By Region:

• North America
• Latin America
• Europe
• South Asia
• East Asia
• Oceania
• Middle East and Africa (MEA)

Frequently Asked Questions

How Big is the Axillary Hyperhidrosis Treatment Market?

The global market might create a revenue of around USD 1.8 billion in 2023.

Which is the Dominant Country for Adoption of Axillary Hyperhidrosis Treatment?

Adoption of such treatments in the United States may increase at 5% CAGR through 2033.

Which is the Leading Regional Market for Axillary Hyperhidrosis Treatment in Europe?

Germany dominates the region and accounted for 22.2% market share in 2022.

How Much Popular is Drug Therapy in Axillary Hyperhidrosis Treatment?

Drug therapy segment held 62.7% of the global market in 2022.

What is the Leading Sales Channel for Axillary Hyperhidrosis Treatment Products?

Retail pharmacies achieved 34.2% of the global sales in 2022.